EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases

Takashi Suzuki, Satoshi Yajima, Akihiko Okamura, Yusuke Taniyama, Yu Ohkura, Koichi Yagi, Takashi Fukuda, Ryo Ogawa, Yasuhiro Tsubosa, Hideaki Shimada

Annals of Thoracic and Cardiovascular Surgery · 2026

DOI: 10.5761/atcs.oa.26-00142 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Thoracic and Cardiovascular Surgery, 2026. Verfasst von Takashi Suzuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Tumor Suppressor Protein p53, Esophageal Neoplasms, Biomarkers, Tumor. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: This multi-institutional study investigated the clinical and prognostic significance of serum p53 antibody (s-p53-Ab) titers in patients with s-p53-Ab-positive esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant chemotherapy (NAC). METHODS: We analyzed 637 patients who underwent surgery at 15 institutions. Patients were divided into upfront surgery (n = 375) and NAC (n = 262) groups and stratified into high-titer (≥9.82 ng/mL) and low-titer (>1.30 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyTumor Suppressor Protein p53Esophageal NeoplasmsBiomarkers, TumorEsophageal Squamous Cell CarcinomaEsophagectomyHumansMaleFemaleMiddle AgedChemotherapy, AdjuvantTime FactorsAgedRetrospective StudiesRisk FactorsNeoplasm StagingTreatment OutcomeProgression-Free Survival

Stichwörter der Autor:innen

esophageal squamous cell carcinomaneoadjuvant chemotherapyserum p53 antibody titers

Substanzen

Tumor Suppressor Protein p53Biomarkers, TumorTP53 protein, human

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Gastroenterology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Department of Digestive Surgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Department of Gastroenterological Surgery, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
  • Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Gastroenterological Surgery, Saitama Cancer Center Hospital, Kitaadachi-gun, Saitama, Japan.

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Suzuki, T., Yajima, S., Okamura, A., Taniyama, Y., Ohkura, Y., Yagi, K., Fukuda, T., Ogawa, R., Tsubosa, Y., & Shimada, H. (2026). Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases. Annals of Thoracic and Cardiovascular Surgery. https://doi.org/10.5761/atcs.oa.26-00142

Vancouver

Suzuki T, Yajima S, Okamura A, Taniyama Y, Ohkura Y, Yagi K, et al. Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases. Annals of Thoracic and Cardiovascular Surgery. 2026. doi:10.5761/atcs.oa.26-00142

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Takashi and Yajima, Satoshi and Okamura, Akihiko and Taniyama, Yusuke and Ohkura, Yu and Yagi, Koichi and Fukuda, Takashi and Ogawa, Ryo and Tsubosa, Yasuhiro and Shimada, Hideaki},
  title = {Impact of High Immunoreactivity on Surgically Treated Serum p53 Antibody-Positive Esophageal Squamous Cell Carcinoma after Neoadjuvant Therapy: A Multi-Institutional Study of 637 Cases},
  journal = {Annals of Thoracic and Cardiovascular Surgery},
  year = {2026},
  doi = {10.5761/atcs.oa.26-00142}
}
Kostenlos starten →